XML 81 R62.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration and License Agreements - Schedule of Significant Changes in Deferred Revenue Balances, Teva Collaboration (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Disaggregation of Revenue [Line Items]      
Increase as a result of cumulative-effect adjustment arising from the adoption of ASC 606 $ (194.5) $ (113.1) $ 244.3
Teva | Accounting Standards Update 2014-09      
Disaggregation of Revenue [Line Items]      
Increase as a result of cumulative-effect adjustment arising from the adoption of ASC 606 48.2    
Increase due to amounts invoiced, excluding amounts recognized as revenue during the period 30.7    
Revenue recognized that was included in deferred revenue at the beginning of the period $ (83.8)